|Day Low/High||36.47 / 36.79|
|52 Wk Low/High||31.67 / 39.43|
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.
Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc.
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
Pfizer Inc. (NYSE:PFE) announced today that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating...
The basic features of a prosperous corporate environment are all around us, but it's become difficult to stick to that narrative amid all the diversions, including from the President.
Global stocks tumbled, with markets in Asia losing all of their year-to-date gains, as China declared it's "not afraid" of an escalating trade war with the United States following President Trump's decision to target $50 billion in China-made goods.
Pfizer Inc. (NYSE:PFE) announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX ®/CHAMPIX ® (varenicline) for smoking cessation in nicotine dependent adolescents 12-19 years of...
Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.
Stocks fall sharply on Thursday after Donald Trump announced a trade action against China that could be worth $60 billion.
Real Money stock picks from Tim Collins, Skip Raschke, Jim Collins and Bret Jensen.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc.
sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC
New reagent serves as a stable, solid alternative to toxic sulfuryl fluoride gas.
Your burning biotech questions answered in our latest mailbag.
Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
We'll answer two of the common questions we have received so far in March.
The most recent short interest data has been released for the 02/26/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.
Pfizer Inc. announced a positive outcome from today's U.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology, Early...
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
Pfizer Inc. today announced the election of Dr.
Jim's back and he's discussing all the portfolio actions we made in the last week plus what we're watching in the market.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.